Participants 65 122 4
postmenopausal patients with metastatic breast carcinoma:
Participants 212 338 4
Breast cancer patients with prior response to endocrine therapy achieve subsequent benefit from additional endocrine therapies
Participants 598 778 6
In 2 multiinstitutional prospective trials, 683 postmenopausal patients were randomized to receive either fadrozole HCL, 1 mg twice daily, or megestrol acetate, 40 mg 4 times daily
Participants 1703 1786 3
postmenopausal patients with metastatic breast carcinoma after one hormonal therapy
